Verrica製藥 VRCA 深 滬
已收盤 02-06 16:00:00 美东时间
6.91
+0.300
+4.54%
華盛通- 最 高7.07
- 今 開6.70
- 成交量 12.42万股
- 最 低 6.70
- 昨 收 6.61
- 總市值 1.10亿
- 52周最高 9.8212
- 市盈率 靜 --
- 換手率 0.78%
- 52周最低 3.28
- 委 比 30.31%
- 總股本 1598.99万
- 歷史最高 232.90
- 量 比 0.71
- 振 幅 5.60%
- 歷史最低 3.816
- 每 手 1
- 風險率 1.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Verrica Pharmaceuticals Files Initial Beneficial Ownership Statement for BKB Growth Investments
Verrica Pharmaceuticals Files Initial Beneficial Ownership Statement for BKB Growth Investments Verrica Pharmaceuticals Inc. has filed an initial statement of beneficial ownership, disclosing BKB Growth Investments, LLC as the beneficial owner. The full filing can be accessed through the link below.
01-27 05:24
Verrica Pharma Announces First Patient Dosed In December 2025 In Global Phase 3 Program Evaluating YCANTH For Treatment Of Common Warts
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity–– Verrica has
01-07 21:09
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals announced the initiation of a global Phase 3 program for YCANTH (VP-102) to treat common warts, with the first patient dosed in December 2025. YCANTH has shown promising results in a Phase 2 trial, achieving 51% complete clearance of warts. The company retains commercial rights for YCANTH outside Japan. Common warts affect over 22 million people in the U.S., with significant commercial potential. Verrica expects YCANTH to ...
01-07 13:00
Verrica Pharmaceuticals Adds Caligan Partner to Board
The latest update is out from Verrica Pharmaceuticals ( ($VRCA) ). On December ...
2025-12-30 19:27
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Brookline Capital Upgrades Verrica Pharmaceuticals to Buy, Announces $17 Price Target
Brookline Capital analyst Kemp Dolliver upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Buy and announces $17 price target.
2025-12-18 20:39
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
2025-12-16 20:05
Verrica Pharmaceuticals Secures $50M Financing Deal
Verrica Pharmaceuticals ( ($VRCA) ) has shared an announcement. On November 23,...
2025-11-25 00:59
Verrica Pharmaceuticals announces $50M PIPE financing
Verrica Pharmaceuticals (VRCA) said it has signed securities purchase agreements for a private investment in public equity (PIPE) that will raise about $50 million in gross proceeds before fees. The f...
2025-11-24 21:40
Verrica Pharmaceuticals shares are trading higher after the company announced a $50 million private placement to retire debt and extend its cash runway.
Verrica Pharmaceuticals shares are trading higher after the company announced a...
2025-11-24 21:01
